Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

BE0974358906
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00X7DCB76
NYXH

Nyxoah S.A.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medtech · THEMEFOLIO: $HLTH
NAME
Nyxoah S.A.
ISIN
BE0974358906
TICKER
NYXH
MIC
XNAS
REUTERS
NYXH.BR
BLOOMBERG
NYXH US
Mon, 18.08.2025       Nyxoah

Mon, 11.08.2025       Nyxoah

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain......
Mon, 11.08.2025       Nyxoah

Nyxoah gibt vorläufige Finanzergebnisse für das zweite Quartal 2025 bekannt Mont-Saint-Guibert, Belgien – 11. August 2025, 07:00 Uhr MESZ  – Nyxoah SA (Euronext Brüssel/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das innovative Technologien zur Behandlung der obstruktiven Schlafapnoe („Obstructive Sleep Apnea“, ......
Mon, 11.08.2025       Nyxoah

Nyxoah Announces Preliminary Results for the Second Quarter of 2025...
Fri, 08.08.2025       Nyxoah

 Nyxoah erhält FDA-Zulassung für Genio®-System zur Behandlung von obstruktiver Schlafapnoe Offizieller Start der Vermarktung in den USA Mont-Saint-Guibert, Belgien – 8. August 2025, 23:30 Uhr MESZ – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das innovative Technologien zur Behandlu......
Fri, 08.08.2025       Nyxoah

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 11:30pm CET / 5:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”),  a medical technology company that develops breakthrough treatm......
Fri, 08.08.2025       Nyxoah

INSIDE INFORMATIONREGULATED INFORMATION...
Tue, 29.07.2025       Nyxoah

Mon, 28.07.2025       Nyxoah

Ergebnisse von Nyxoahs pivolater DREAM-Studie im Journal of Clinical Sleep Medicine veröffentlicht Mont-Saint-Guibert, Belgien - 28. Juli 2025, 22:05 Uhr MESZ – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das innovative Technologien zur Behandlung der obstruktiven Schlafapnoe („Obstr......
Mon, 28.07.2025       Nyxoah

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today ......
Silent Ad
Fri, 27.06.2025       Nyxoah

Fri, 13.06.2025       Nyxoah

REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET...
Fri, 30.05.2025       Nyxoah

                ...
Fri, 23.05.2025       Nyxoah

Wed, 14.05.2025       Nyxoah

Nyxoah Reports First Quarter Financial and Operating Results  Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress  Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or th......
Wed, 14.05.2025       Nyxoah

Nyxoah gibt Finanzergebnisse und operatives Update für das erste Quartal bekannt  Das Unternehmen ist im Zeitplan für die voraussichtliche PMA-Zulassung im zweiten Quartal 2025 Die FDA-Validierungsanforderungen wurden erfolgreich erfüllt - zurzeit findet die abschließende Standortinspektion statt  Mont-Saint-Guibert, Belgien - 14. Mai 2025, 7:00......
Wed, 14.05.2025       Nyxoah

Mon, 12.05.2025       Nyxoah

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Fri, 09.05.2025       Nyxoah

                ...
Fri, 09.05.2025       Nyxoah

REGULATED INFORMATIONMay 9, 2025, 7:00am CET / 1:00am ET...
Silent Ad
Tue, 06.05.2025       Nyxoah

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Tue, 22.04.2025       Nyxoah

NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Wed, 16.04.2025       Nyxoah

INSIDE INFORMATIONREGULATED INFORMATION...
Tue, 15.04.2025       Nyxoah

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Tue, 08.04.2025       Nyxoah

NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Tue, 08.04.2025       Nyxoah

 Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for O......
Tue, 08.04.2025       Nyxoah

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter...
Mon, 07.04.2025       Nyxoah

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or "the Company") (NASDAQ: NYXH) for violations of the securities laws....
Sun, 06.04.2025       Nyxoah

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or “the Company”) (NASDAQ: NYXH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose i...
Mon, 31.03.2025       Nyxoah

NEW YORK, March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Wed, 26.03.2025       Nyxoah

Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA Mont-Saint-Guibert, Belgien – 26. März 2025 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das innovative Technologien zur Behandlung der obstruktiven Schlafapnoe („Obstructive Sleep Apnea“, OSA) mithilfe von Neurostim......
Wed, 26.03.2025       Nyxoah

FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food a......
Wed, 26.03.2025       Nyxoah

Thu, 13.03.2025       Nyxoah

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in the First Quarter 2025 Mont-Saint-Guibert, Belgium – March 13, 2025, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that dev......
Thu, 13.03.2025       Nyxoah

Nyxoah gibt Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 bekannt und informiert über die Unternehmensentwicklung  FDA PMA-Antragsprüfung vor dem Abschluss  Positioniert für die Markteinführung in den USA im ersten Quartal 2025 Mont-Saint-Guibert, Belgien - 13. März 2025, 7:00 Uhr MEZ – Nyxoah SA (Euronext Brussels/Nasdaq: N......
Thu, 13.03.2025       Nyxoah

Mon, 10.03.2025       Nyxoah

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025...
Wed, 19.02.2025       Nyxoah

Nyxoah gibt die Markteinführung der innovativen Genio®-Therapie im Nahen Osten bekannt Der erste Patient hat im Saudi German Hospital in Dubai, Vereinigte Arabische Emirate, ein Genio-Implantat erhalten Mont-Saint-Guibert, Belgien – 19. Februar 2025, 07:05 Uhr MEZ – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ei......
Wed, 19.02.2025       Nyxoah

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology comp......
Wed, 19.02.2025       Nyxoah

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates...
Wed, 19.02.2025       Nyxoah

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates...
Mon, 20.01.2025       Nyxoah

               ...
Fri, 20.12.2024       Nyxoah

               ...
Fri, 13.12.2024       Nyxoah

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 08:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alterna......
Fri, 13.12.2024       Nyxoah

Nyxoah gibt die Markteinführung der innovativen Genio®-Therapie in England bekannt Die ersten Patienten haben an den UCLH in London ein Genio-Implantat erhalten Mont-Saint-Guibert, Belgien – 13. Dezember 2024, 08:05 Uhr MEZ – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) („Nyxoah” oder das „Unternehmen”), ein Medizintechnikunternehmen, das sich auf ......
Fri, 13.12.2024       Nyxoah

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London...
Wed, 27.11.2024       Nyxoah

Wed, 20.11.2024       Nyxoah

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference...
Tue, 19.11.2024       Nyxoah

REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET...
Mon, 18.11.2024       Nyxoah

                ...